MAGELLAN APPOINTS NEW SHARE REGISTRY Magellan is pleased to announce that we have appointed Bio101 – a leading provider of financial, accounting, and company secretarial services to the biotechnology and life sciences sector – to provide our new secure share registry office service. The registry will hold details of members’ shareholdings as well as a library […]
Magellan are pleased to announce the results of our Phase 1/2 allogenic trial. The research findings are published in Osteoarthritis and Cartilage Open the open-access journal of Osteoarthritis Research Society International (OARSI), which publishes the evidence-based, international consensus guidelines on osteoarthritis management.
Australian Health Minister announced a $7 million grant to Magellan Stem Cells – read more here
Should you want further information regarding our results or media release please email info@magellanstemcells.com.au or call 03 9270 8080.
